BrightEdge Venture Fund

BrightEdge Venture Fund is the American Cancer Society’s innovation and impact venture capital arm, investing in cancer-related innovation. It backs early- and later-stage U.S. biotechnology, life sciences, HealthTech, medical device, oncology and pharmaceutical companies, with themes including prevention, early detection, patient access, affordability, care breakthroughs and treatment adherence. The fund is relevant for founders building technology-enabled or science-based medicines and solutions with measurable patient-centric impact and financial return potential.